OptimizeRx Q1 Adj $(0.11) Beats $(0.13) Estimate, Sales $19.69M Beat $18.13M Estimate
OptimizeRx Q1 Adj $(0.11) Beats $(0.13) Estimate, Sales $19.69M Beat $18.13M Estimate
OptimizerX第一季度調整後的美元（0.11美元）超過預期（0.13美元），銷售額1,969萬美元超過預期的1,813萬美元
OptimizeRx (NASDAQ:OPRX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 22.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $19.69 million which beat the analyst consensus estimate of $18.13 million by 8.60 percent. This is a 51.43 percent increase over sales of $13.00 million the same period last year.
OptimizerX（納斯達克股票代碼：OPRX）公佈的季度虧損爲每股0.11美元，比分析師普遍預期的0.13美元（0.13美元）高出15.38％。與去年同期每股虧損0.09美元（0.09）相比，下降了22.22％。該公司公佈的季度銷售額爲1,969萬美元，比分析師共識估計的1,813萬美元高出8.60％。這比去年同期的1,300萬美元銷售額增長了51.43％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。